Foresight LabsA jacket, two journeys

European Economic AreaREACHCLP

ECHA PBT Expert Group Highlights Bioaccumulation Assessment Strategies For Tougher Substances

ECHA’s PBT Expert Group discussed bioaccumulation assessment strategies, including NAMs and non-vertebrate tests, with implications for REACH and CLP dossiers.

Dr Steven Brennan

2 min readAI-drafted, expert reviewed

Laboratory bench with glassware and a notebook

ECHA’s PBT Expert Group says bioaccumulation assessment strategies are evolving, with more reliance on New Approach Methodologies (NAMs) and broader organism coverage, affecting how PBT/vPvB and PMT/vPvM evidence is built for regulatory decisions under REACH and CLP.

Why Bioaccumulation Assessment Strategies Are Changing

ECHA notes that the approach needs to work for substances that are hard to test, including cases where fish studies may not capture broader bioaccumulation concerns. Guidance updates in 2023 and 2024 add Hyalella as a test organism and incorporate toxicokinetic data to support evaluation in air-breathing organisms such as mammals.

What Was Discussed: NAMs And Tiered Testing Options

At the 41st PBT Expert Group meeting, ECHA reports presentations on an “Integrated strategy for the assessment of aquatic and terrestrial bioaccumulation” project. The project analysed 231 chemicals and recommended consensus values for log Kow and log Koa.

The tiered approach discussed screening criteria and QSAR predictions alongside an in vitro clearance assay with fish cell lines (OECD TG 319A/B) and an invertebrate bioconcentration test (OECD TG 321). For air-breathing organisms, an in vitro intrinsic clearance assay using rat hepatocytes or S9 was discussed in combination with IVIVE, with in vivo testing positioned as a later step when results remain inconclusive. Caren Rauert (UBA) is quoted as saying: “For most substances a non-vertebrate test option would already be available”.

Implications For Compliance Teams Across The Value Chain

The note is non-binding, but it signals expectations for dossier evidence. Teams preparing REACH registrations, updates, or risk assessments can review fish-only rationales, document applicability domains for any NAMs used, and capture decision logic for combining predictions and test results. ECHA notes the project report will be published early 2026 on the UBA website.

Questions about this change

What are bioaccumulation assessment strategies in EU chemicals regulation?

Bioaccumulation assessment strategies set out how to judge whether a substance builds up in organisms, supporting PBT/vPvB and PMT/vPvM conclusions under REACH and CLP. Evidence may include screening criteria, QSAR predictions, laboratory tests, and kinetic data. The aim is consistent, traceable decisions for environmental hazards across the EU regulatory system.

How should companies prepare for ECHA’s evolving bioaccumulation assessment strategies?

Start by identifying substances where your dossiers rely mainly on fish studies for bioaccumulation. Check whether alternative methods, such as OECD TG 319A/B or 321, could be relevant and document applicability limits. Record how you combine predictions and test results, and align updates with current ECHA guidance before submission deadlines.

Dr Steven Brennan

CEO and co-founder of Foresight, and a co-opted member of ECHA's Committee for Socio-economic Analysis. He holds a PhD in chemical engineering.

More from Dr Steven Brennan

Join 3,500+ professionals staying ahead

Foresight Weekly brings the week's regulatory changes across chemicals, product safety, sustainability, ESG and EHS into one email.

Free. Unsubscribe at any time.

Read by professionals at

  • Boeing
  • AstraZeneca
  • Siemens
  • PepsiCo
  • SpaceX